Literature DB >> 895764

Inefficacy of immediate node dissection in stage 1 melanoma of the limbs.

U Veronesi, J Adamus, D C Bandiera, I O Brennhovd, E Caceres, N Cascinelli, F Claudio, R L Ikonopisov, V V Javorskj, S Kirov, A Kulakowski, J Lacoub, F Lejeune, Z Mechl, A Morabito, I Rodé, S Sergeev, E van Slooten, K Szcygiel, N N Trapeznikov.   

Abstract

From September, 1967, to January, 1974, a clinical trial was carried out by the WHO Melanoma Group to evaluate the efficacy of elective lymph-node dissection in the treatment of malignant melanoma of the extremities with clinically uninvolved regional lymph nodes. Treatment was prospectively randomized: 267 patients to excision of primary melanoma and immediate regional-lymph-node dissection and 286 to excision of primary melanoma and regional-lymph-node dissection at the time of appearance of metastases. The statistical analysis showed no difference in survival between the two groups of patients, regardless of how the data were analyzed (according to sex, site of origin, maximum diameter of primary tumor or Clark's level or Breslow's thickness). Elective lymph-node dissection in malignant malanoma of the limbs does not improve the prognosis and is not recommended when patients can be followed at intervals of three months.

Entities:  

Mesh:

Year:  1977        PMID: 895764     DOI: 10.1056/NEJM197709222971202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  72 in total

1.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

2.  Sentinel node biopsy in breast cancer. Effect on patients must be considered.

Authors:  H Thornton
Journal:  BMJ       Date:  1999-02-27

Review 3.  Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Authors:  Sanjay P Bagaria; Mark B Faries; Donald L Morton
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

4.  MSLT-I-response of clinical trial investigators.

Authors:  James C Yang; Richard M Sherry
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

5.  [Selective sentinel node biopsy in melanoma].

Authors:  Luis Cabañas Navarro
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

6.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial.

Authors:  Patrick Twomey
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

7.  Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma.

Authors:  Alexander Stojadinovic; Peter J Allen; Bryan M Clary; Klaus J Busam; Daniel G Coit
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

8.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

9.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

Review 10.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.